Vertex Pharmaceuticals Inc annual shares outstanding for fiscal TTM was 256 million shares, a decrease of 0.8% from 258 million shares in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Shares Outstanding (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (M) | 256M | 258M | 258M | 260M | 259M | 260M | 263M | 261M | 259M | 253M | 245M | 241M | 235M | 225M | 212M | 209M | 200M | 173M | 141M | 129M | 113M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Shares Outstanding (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (M) | 256M | 256M | 258M | 259M | 260M | 260M | 261M | 258M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More VRTX metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow
All VRTX financial statements → Interactive VRTX charts →
About TickerBase · Data methodology & sources